Juan Cundom

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +14

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 235 citations

Medicine, Oncology, Pharmacology +17

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso et al. · Journal of Clinical Oncology · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes et al. · Journal of Clinical Oncology · 2024 · 55 citations · Full text

Medicine, Oncology, Pharmacology +14

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Hepatology · 2025 · 49 citations

Medicine, Oncology, Pharmacology +7